JOURNAL ARTICLE

Dr Yellapragada SubbaRow: the forgotten figure in the history of methotrexate.

  • Published In: Rheumatology, 2023, v. 62, n. 4. P. 1364 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Bagri, Narendra K; Ramanan, Atreya; Ramanan, Athimalaipet V 3 of 3

Abstract

The article recognizes the contributions of Doctor Yellapragada SubbaRow of India to the widespread use of low-dose methotrexate (MTX) in the treatment of rheumatic diseases in adults and children. It discusses his role in the development of aminopterin, a folic acid antagonist aimed at treating leukaemia in children, led by Sydney Farber at Boston Children's Hospital. It describes how he replaced the compound and renamed it as MTX to lessen the toxicity of aminopterin.

Additional Information

  • Source:Rheumatology. 2023/04, Vol. 62, Issue 4, p1364
  • Document Type:Editorial
  • Subject Area:History
  • Publication Date:2023
  • ISSN:1462-0324
  • DOI:10.1093/rheumatology/keac520
  • Accession Number:162940925

Looking to go deeper into this topic? Look for more articles on EBSCOhost.